Stockreport

Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus [Yahoo! Finance]

Immunovant, Inc.  (IMVT) 
PDF The reported figure is also wider than the year-ago quarter's loss of 46 cents per share. Currently, Immunovant does not have any approved product in its portfolio. As [Read more]